Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for HilleVax, Inc. (HLVX : NSDQ)

• Company Description    HilleVax Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax Inc. is based in BOSTON. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $2.10 Daily Weekly Monthly 20 Day Moving Average: 419,862 shares Shares Outstanding: 50.14 (millions) Market Capitalization: $105.30 (millions) Beta: 0.76 52 Week High: $2.15 52 Week Low: $1.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.38% 5.28% 12 Week 24.26% 4.52% Year To Date 1.45% -4.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 HARRISON AVE SUITE 500 - BOSTON,MA 02118 USA ph: 617-213-5054 fax: - ir@hillevax.com http://www.hillevax.com

• General Corporate Information    Officers Robert Hershberg - Chairman; President and Chief Executive Officer Shane Maltbie - Chief Financial Officer Shelley Chu - Director Nanette Cocero - Director Gary Dubin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 43157M102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 50.14 Most Recent Split Date: (:1) Beta: 0.76 Market Capitalization: $105.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.58 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.70 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 87.63% vs. Previous Quarter: 65.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -51.86 12/31/24 - -66.87 ROA 06/30/25 - - 03/31/25 - -41.45 12/31/24 - -52.10 Current Ratio 06/30/25 - - 03/31/25 - 25.32 12/31/24 - 10.84 Quick Ratio 06/30/25 - - 03/31/25 - 25.32 12/31/24 - 10.84 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 3.01 12/31/24 - 3.10 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©